Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2018-04-19 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
2017年度独立董事述职报告（王石）
Board/Management Information Classification · 95% confidence The document is titled '2017 年度独立董事述职报告' which translates to '2017 Annual Independent Director's Work Report'. It details the independent director's activities, opinions on board meetings, attendance, investigations, and efforts to protect shareholder interests during the 2017 fiscal year. The content focuses on the independent director's duties and opinions rather than financial statements or audit results. It is a report on board/management activities and governance from the perspective of an independent director. The document length is 3132 characters, which is relatively short but contains substantive content about board and management activities rather than just an announcement. Therefore, it fits best under Board/Management Information (MANG).
2018-04-19 Chinese
独立董事制度（2018年4月）
Governance Information Classification · 100% confidence The document is titled '深圳华大基因股份有限公司 独立董事制度' which translates to 'Shenzhen BGI Genomics Co., Ltd. Independent Director System'. It is a detailed policy document outlining the rules, qualifications, nomination, election, duties, and working conditions of independent directors at the company. The content is focused on governance structure, board composition, director responsibilities, and compliance with relevant laws and regulations. There is no financial data, earnings information, or report publication announcement. The document is a governance-related internal policy rather than a report or announcement. Therefore, the most appropriate classification is Governance Information (CGR). The document length (7647 characters) supports it being a full policy document rather than a brief announcement.
2018-04-19 Chinese
关于举行2017年度网上业绩说明会的公告
Investor Presentation Classification · 95% confidence The document is an announcement about holding the 2017 annual online earnings presentation (业绩说明会) by Shenzhen BGI Genomics Co., Ltd. It references that the 2017 Annual Report has already been disclosed on April 20, 2018, and invites investors to participate in the online earnings explanation meeting on April 27, 2018. The document is short (546 characters) and serves as a notice for an upcoming investor presentation event rather than the report itself or detailed financial data. Therefore, it fits best as an Investor Presentation (IP) announcement.
2018-04-19 Chinese
关于2018年度公司及下属子公司向银行申请综合授信额度及担保事项的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the company's and its subsidiaries' application for a comprehensive credit line and guarantee matters for the year 2018. It details the credit limits applied for from various banks, the guarantee amounts, the financial status of the subsidiaries involved, and the approvals from the board, independent directors, and supervisory board. The document is a formal announcement of financing activities and guarantees, not a financial report or audit. It does not contain comprehensive financial statements or detailed financial performance data but focuses on capital/financing updates and related approvals. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length is 5471 characters, which is sufficient to contain substantive information rather than a mere announcement of a report publication or a regulatory filing. Hence, the classification is CAP with high confidence.
2018-04-19 Chinese
中信证券股份有限公司关于公司2017年度募集资金存放与实际使用情况的核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2017年度募集资金存放与实际使用情况的核查报告" which translates to "2017 Annual Report on the Custody and Actual Use of Raised Funds." It is issued by CITIC Securities as the sponsor for Shenzhen BGI Genomics Co., Ltd. The document details the management, storage, and actual use of funds raised from the company's initial public offering (IPO) in 2017. It includes detailed financial figures, regulatory references, and audit opinions related to the use of raised funds. The document is a standalone audit and verification report focusing on the use of IPO proceeds, not a full annual report or earnings release. It aligns with the definition of an Audit Report / Information (AR) as it provides audit verification and compliance information about the use of raised funds, separate from the full annual report. The document length (7117 characters) and detailed financial data support this classification rather than a simple announcement or regulatory filing. FY 2017
2018-04-19 Chinese
募集资金存放与实际使用情况鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "募集资金存放与实际使用情况鉴证报告" which translates to "Verification Report on the Deposit and Actual Use of Raised Funds" for the year ending December 31, 2017. It includes detailed information about the company's fundraising activities, the use of raised funds, and compliance with regulatory requirements from the China Securities Regulatory Commission and Shenzhen Stock Exchange. The report is prepared by an accounting firm (Ernst & Young Hua Ming) providing an attestation on the use of funds. This type of document is a specialized audit or verification report focusing on the management and use of capital raised by the company, rather than a full annual report or earnings release. It is not a general financial statement but a standalone audit/verification report related to capital usage. Therefore, the most appropriate classification is Audit Report / Information (AR). The document length (8752 characters) and content confirm it is a full report, not just an announcement or certification letter, so it is not RPA or RNS. FY 2017
2018-04-19 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.